Welcome to our dedicated page for Adagio Medical SEC filings (Ticker: ADGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adagio Medical Holdings, Inc. (Nasdaq: ADGM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to official information about this medical device issuer. Adagio’s filings describe its focus on catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology for cardiac arrhythmias and provide detail on its corporate structure, governance, and capital markets activity.
Through Form 8-K current reports, Adagio furnishes information on material events such as private placement financings, preliminary clinical data releases, and key leadership appointments. For example, recent 8-K filings reference the Securities Purchase Agreement for a private placement of common stock and warrants, the closing of that financing, and press releases announcing acute results from the FULCRUM-VT pivotal IDE study and the completion of enrollment in that trial. Other 8-Ks disclose changes in executive roles, including the expansion of the Chief Business Officer’s responsibilities to include Chief Financial Officer, and the scheduling of the company’s annual meeting.
Adagio’s DEF 14A definitive proxy statement provides additional context on board elections, auditor ratification, executive compensation, security ownership, and the business combination that created Adagio Medical Holdings, Inc. It also outlines stockholder voting procedures and meeting logistics. Periodic reports such as Forms 10-Q and 10-K, when viewed alongside these current reports, give a fuller picture of Adagio’s financial condition and risk disclosures, although they are not reproduced in the text above.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, clinical and regulatory milestones, and financing structures, helping readers interpret complex documents more quickly. Users can also review filings related to equity issuances and warrant terms, as well as governance documents that frame Adagio’s ongoing reporting obligations as an emerging growth company listed on The Nasdaq Stock Market LLC.
Adagio Medical Holdings, Inc. reported results from its 2025 Annual Meeting of Stockholders held on December 15, 2025. Of the 21,179,637 shares outstanding as of the record date, 13,862,436 shares, or 65.45%, were present or represented by proxy.
Stockholders elected Todd Usen and James L. Cox, M.D. as directors to serve until the 2028 annual meeting and until their successors are elected and qualified. They also approved the ratification of WithumSmith+Brown, PC as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
Adagio Medical Holdings, Inc. reported that its Chief Executive Officer and director acquired 207,315 shares of its common stock in an open market transaction on 12/12/2025.
The shares were purchased at a weighted average price of $1.09 per share, with individual trade prices ranging from $0.9258 to $1.14101. After this transaction, the reporting person directly owned 207,315 shares of Adagio Medical common stock.
Adagio Medical Holdings, Inc. is registering up to 27,831,335 shares of common stock for resale by existing investors, including 5,798,072 outstanding shares, 3,994,434 shares issuable upon exercise of pre-funded warrants, and 18,038,829 shares issuable upon exercise of milestone warrants. These securities were issued in an October 2025 private placement that provided approximately $19 million in gross proceeds, with up to about $31 million more potentially available if all milestone warrants are exercised for cash at $1.71 per share.
The company will not receive any proceeds from resales of these shares, only from any future cash exercises of the pre-funded or milestone warrants. Adagio develops catheter-based ultra-low temperature cryoablation technology targeting ventricular tachycardia, a life‑threatening heart rhythm disorder. As of October 31, 2025, it had 21,179,637 shares of common stock outstanding. Adagio is an “emerging growth company” and “smaller reporting company,” allowing it to use scaled disclosure and certain reporting exemptions.
Adagio Medical Holdings, Inc. reported that a director acquired a non-qualified stock option to purchase 90,000 shares of common stock on 12/11/2025 at an exercise price of $0.8779 per share.
The option expires on 12/10/2035 and is held directly. The shares underlying the option will vest in 36 equal monthly installments starting January 11, 2026, subject to the director continuing to provide services on each vesting date.
Adagio Medical Holdings, Inc. filed an initial insider ownership report for a director effective 12/11/2025. The filing shows that the reporting person is a director of the company and that no securities are beneficially owned in either non-derivative or derivative form. The remarks section notes Exhibit 24.1 as a power of attorney, under which Deborah Kaster signs as attorney-in-fact for the reporting person.
Adagio Medical Holdings, Inc. has filed a prospectus supplement covering the potential resale of up to 31,818,652 shares of common stock by selling stockholders. This total includes 73,333 Registration Delay Shares already issued, up to 31,145,319 shares issuable upon conversion of 13% senior secured convertible notes with a $10.00 per share conversion price, and up to 600,000 shares issuable upon exercise of warrants with a $24.00 per share exercise price. These securities were issued or are issuable under prior financing agreements, and this document updates the existing prospectus with a recent Current Report on Form 8-K. The company’s common stock trades on Nasdaq under the symbol ADGM, with a last reported price of $0.8779 per share on December 11, 2025.
Adagio Medical Holdings, Inc. filed a prospectus supplement covering the resale of up to 67,963,695 shares of its common stock by existing holders. The shares include previously issued stock, as well as shares issuable upon exercise of pre-funded warrants and other warrants, and upon conversion of 13% senior secured convertible notes, all tied to prior financing and business combination agreements. The supplement incorporates a recent Current Report on Form 8-K into the existing prospectus and must be read together with that document. Adagio’s common stock trades on the Nasdaq Capital Market under the symbol ADGM, and the last reported sales price on December 11, 2025 was $0.8779 per share. The company is classified as an emerging growth company and highlights that investing in its securities involves a high degree of risk.
Adagio Medical Holdings, Inc. has filed a Form S-3 to register 27,831,335 shares of common stock for resale by existing selling stockholders, including shares underlying pre-funded and milestone warrants issued in an October 2025 private placement.
The company is a medical device developer focused on ultra-low temperature cryoablation technology for treating ventricular tachycardia. The private placement raised approximately $19 million in gross proceeds and included 18,038,829 milestone warrants with a cash exercise price of $1.71 per share and pre-funded warrants at $0.0001 per share. Adagio will not receive proceeds from stockholder resales but may receive additional cash if these warrants are exercised.
As of October 31, 2025, Adagio had 21,179,637 shares of common stock outstanding. The company qualifies as an emerging growth company and smaller reporting company, allowing reduced reporting requirements.
Adagio Medical Holdings (ADGM) filed a prospectus supplement for the resale of up to 31,818,652 shares of common stock by selling stockholders. This covers 73,333 Registration Delay Shares, up to 31,145,319 shares issuable upon conversion of 13% senior secured convertible notes at $10.00 per share, and up to 600,000 shares issuable upon exercise of warrants at $24.00 per share. The supplement attaches the company’s latest Quarterly Report on Form 10‑Q.
In the quarter ended September 30, 2025, Adagio reported a net loss of $10.1 million, cash and cash equivalents of $4.7 million, and stockholders’ deficit of $1.3 million. The company announced a private placement in October 2025 for approximately $19 million in aggregate gross proceeds, and management states available cash, including those proceeds, is sufficient for at least 12 months from the report date. Shares outstanding were 21,179,637 as of November 10, 2025. ADGM last closed at $0.8724 on November 11, 2025.